b-cell-derived lymphotoxin promotes castration-resistant prostate cancer 
prostate cancer cap progresses prostatic intraepithelial neoplasia locally invasive adenocarcinoma castration-resistant metastatic carcinoma1 although radical prostatectomy radiation androgen ablation effective therapies androgen-dependent cap metastatic castration-resistant cap major complication high mortality2 androgens stimulate growth survival prostate epithelium early cap although patients initially respond androgen ablation many develop castration-resistant cap within - months2 despite extensive studies mechanisms underlying emergence castration-resistant cap remain poorly understood elucidation critical developing improved therapies curiously castration-resistant cap remains androgen-receptor dependent potent androgen-receptor antagonists induce tumour regression castrated mice3 role inflammation castration-resistant cap addressed although reported intrinsic nf-kappa b activation supports growth4 inflammation localized protective reaction injury infection also pathogenic role many diseases including cancer5 whereas acute inflammation critical host defence chronic inflammation contributes tumorigenesis metastatic progression inflammation-responsive kappa b kinase ikk-beta target nf-kb important tumour-promoting functions within malignant cells inflammatory cells6 latter including macrophages lymphocytes important elements tumour microenvironment7- mechanisms underlying recruitment remain obscure although thought depend chemokine cytokine production10 found cap progression associated inflammatory infiltration activation ikk-alpha stimulates metastasis nf-kappa b-independent cell autonomous mechanism11 show androgen ablation causes infiltration regressing androgen-dependent tumours leukocytes including b cells ikk-beta activation results production cytokines activate ikk-alpha stat3 cap cells enhance hormone-free survival 
